CDIO
Cardio Diagnostics Holdings Inc (CDIO)
Healthcare • NASDAQ • $1.83+1.10%
- Symbol
- CDIO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $1.83
- Daily Change
- +1.10%
- Market Cap
- $5.42M
- Trailing P/E
- N/A
- Forward P/E
- -7.32
- 52W High
- $7.91
- 52W Low
- $0.97
- Analyst Target
- N/A
- Dividend Yield
- N/A
- Beta
- 2.26
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS ca…
Company websiteResearch CDIO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.